Prelude Therapeutics annual total assets
2019
2020
2021
2022
2023
2024
2025
Prelude Therapeutics Total Assets Growth & History (PRLD)
Prelude Therapeutics's total assets was $141.3M for fiscal 2025.
View full Prelude Therapeutics company overviewPrelude Therapeutics annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $141.3M | −$34.2M | −19.49% |
| 2024 | 2024-12-31 | $175.5M | −$102.2M | −36.79% |
| 2023 | 2023-12-31 | $277.7M | $57.2M | +25.93% |
| 2022 | 2022-12-31 | $220.5M | −$84.6M | −27.73% |
| 2021 | 2021-12-31 | $305.1M | $81.5M | +36.45% |
| 2020 | 2020-12-31 | $223.6M | $201.7M | +922.31% |
| 2019 | 2019-12-31 | $21.9M | — | — |
Prelude Therapeutics quarterly total assets
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $189.4M | $74.4M | +64.78% |
| Q1 2026 | 2026-03-31 | $119.6M | −$21.6M | −15.30% |
| Q4 2025 | 2025-12-31 | $141.3M | −$34.2M | −19.49% |
| Q3 2025 | 2025-09-30 | $94.8M | −$102.5M | −51.95% |
| Q2 2025 | 2025-06-30 | $114.9M | −$109.4M | −48.76% |
| Q1 2025 | 2025-03-31 | $141.3M | −$105.8M | −42.83% |
| Q4 2024 | 2024-12-31 | $175.5M | −$102.2M | −36.79% |
| Q3 2024 | 2024-09-30 | $197.2M | −$61.3M | −23.71% |
| Q2 2024 | 2024-06-30 | $224.3M | −$56.3M | −20.07% |
| Q1 2024 | 2024-03-31 | $247.1M | $48.8M | +24.60% |
| Q4 2023 | 2023-12-31 | $277.7M | $57.2M | +25.93% |
| Q3 2023 | 2023-09-30 | $258.5M | $16.2M | +6.68% |
| Q2 2023 | 2023-06-30 | $280.6M | $21.6M | +8.32% |
| Q1 2023 | 2023-03-31 | $198.3M | −$82.4M | −29.34% |
| Q4 2022 | 2022-12-31 | $220.5M | −$84.6M | −27.73% |
| Q3 2022 | 2022-09-30 | $242.3M | −$88.9M | −26.84% |
| Q2 2022 | 2022-06-30 | $259.1M | −$90.5M | −25.90% |
| Q1 2022 | 2022-03-31 | $280.7M | −$89.2M | −24.11% |
| Q4 2021 | 2021-12-31 | $305.1M | $81.5M | +36.45% |
| Q3 2021 | 2021-09-30 | $331.2M | $91.5M | +38.19% |
| Q2 2021 | 2021-06-30 | $349.6M | — | — |
| Q1 2021 | 2021-03-31 | $369.8M | — | — |
| Q4 2020 | 2020-12-31 | $223.6M | $201.7M | +922.31% |
| Q3 2020 | 2020-09-30 | $239.7M | — | — |
| Q4 2019 | 2019-12-31 | $21.9M | — | — |
Prelude Therapeutics total assets trends
Over the last five fiscal years, Prelude Therapeutics's total assets decreased from $223.6M to $141.3M, a change of −$82.3M. The latest reported quarter, Q2 2026, shows $189.4M.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prelude Therapeutics source filings ↗Community posts
Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects t ...